抗VEGF玻璃体腔注射（雷珠单抗）
眼科项目
≈ ¥4500-6500
(≈ $630-910)
大约30-60分钟
免责声明：本站为医疗服务机构，页面信息部分由AI协助制作。健康相关信息不构成医疗建议。如有任何疑问，请咨询医疗专业人士。详情见免责声明
项目介绍
抗VEGF玻璃体腔注射（雷珠单抗）在一般公立医院参考费用约¥3150-5200，三甲医院参考费用约¥4500-6500，常用于相关诊断评估与就医安排，费用随医院及地区有所差异。
主要用途
Primary clinical use is intravitreal administration of ranibizumab (a recombinant humanized monoclonal antibody fragment) to inhibit vascular endothelial growth factor-A (VEGF-A) in the eye. Indications include: neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV). Treatment aims to reduce vascular leakage, inhibit abnormal blood vessel growth, stabilize or improve visual acuity, and prevent disease progression.
正常值范围
Not applicable — anti-VEGF intravitreal injection (ranibizumab) is a therapeutic procedure, not a diagnostic laboratory test with quantitative biomarker values. There is no 'normal range' for ranibizumab concentration in clinical practice; dosing is standardized (0.5 mg/0.05 mL per injection), and systemic drug levels are not routinely monitored.
偏低可能原因
N/A — this is not a measurable serum or ocular fluid assay; 'low value' does not apply. However, subtherapeutic effect may result from: 1) Inadequate dosing frequency (e.g., extended dosing intervals beyond disease activity), 2) Poor drug penetration due to vitreous opacities or fibrosis, 3) Development of neutralizing anti-ranibizumab antibodies (rare), 4) Non-adherence to treatment protocol, 5) Underlying disease resistance (e.g., persistent VEGF-independent angiogenesis).
偏高可能原因
N/A — no clinically defined 'high value' exists. Potential concerns related to excessive exposure include: 1) Off-label repeated injections without evidence-based justification, 2) Accidental overdose (e.g., dosing error — extremely rare with prefilled syringes), 3) Systemic absorption leading to elevated free VEGF inhibition (theoretical risk of hypertension or thromboembolism), 4) Concomitant use of other anti-angiogenic agents, 5) Pre-existing systemic conditions exacerbating anti-VEGF effects (e.g., uncontrolled hypertension, recent stroke).